-- Harmony Biosciences (HRMY) shares fell over 6% in Thursday trading after the company's Q1 earnings and revenue fell short of analysts' consensus.
The company reported Q1 earnings of $0.55 per diluted share, down from $0.78 a year earlier.
Analysts polled by FactSet expected $0.69.
Net product revenue for the quarter ended March 31 was $215.4 million, up from $184.7 million a year earlier.
Analysts expected revenue of $220.8 million.
As of March 31, the company said it had $870.5 million in cash, cash equivalents, and investments.
The company reiterated its 2026 WAKIX net revenue guidance of $1 billion to $1.04 billion. Analysts expect $1.01 billion.
Price: $29.52, Change: $-3.26, Percent Change: -9.95%